Halaven (Eribulin)

Halaven (eribulin) is indicated for the treatment of specific advanced solid tumors after prior therapy.

• Metastatic breast cancer that has progressed following anthracycline and taxane regimens.
• Unresectable or metastatic liposarcoma in patients who have received prior chemotherapy.
• Use as part of a treatment plan defined by an oncologist for patients with limited therapeutic options.
• May be considered when disease progression occurs despite standard first‑line agents.

The safety profile of eribulin includes a range of adverse events that vary in frequency and severity.

Common

• Fatigue
• Neutropenia
• Nausea
• Peripheral neuropathy

Serious

• Febrile neutropenia
• Cardiac dysfunction (e.g., reduced ejection fraction)
• Severe liver enzyme elevation

When prescribing eribulin, clinicians should evaluate several precautionary factors to minimize risk.

• Baseline complete blood count; monitor for neutropenia and anemia.
• Assess cardiac function before initiation and periodically during therapy.
• Evaluate liver function; dose adjustments may be required for hepatic impairment.
• Use caution in patients with pre‑existing peripheral neuropathy.
• Avoid use during pregnancy; teratogenic potential is unknown.
• Monitor for signs of infection, especially febrile episodes.
• Consider dose reduction or interruption if severe toxicities develop.

Eribulin may interact with other medications, influencing its efficacy or safety.

Avoid

• Concurrent use with strong CYP3A4 inducers (e.g., rifampin) that may reduce eribulin exposure.
• Co‑administration with other myelosuppressive agents without dose adjustment.

Use with caution

• Anticoagulants, as thrombocytopenia may increase bleeding risk.
• Drugs that prolong QT interval; monitor cardiac rhythm.
• Vaccines containing live attenuated organisms due to immunosuppression.